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Abstract
If genome sequencing is performed in health care, in theory the opportunity arises to take a further look at the data:
opportunistic genomic screening (OGS). The European Society of Human Genetics (ESHG) in 2013 recommended that
genome analysis should be restricted to the original health problem at least for the time being. Other organizations have
argued that ‘actionable’ genetic variants should or could be reported (including American College of Medical Genetics and
Genomics, French Society of Predictive and Personalized Medicine, Genomics England). They argue that the opportunity
should be used to routinely and systematically look for secondary findings—so-called opportunistic screening. From a
normative perspective, the distinguishing characteristic of screening is not so much its context (whether public health or
health care), but the lack of an indication for having this specific test or investigation in those to whom screening is offered.
Screening entails a more precarious benefits-to-risks balance. The ESHG continues to recommend a cautious approach to
opportunistic screening. Proportionality and autonomy must be guaranteed, and in collectively funded health-care systems
the potential benefits must be balanced against health care expenditures. With regard to genome sequencing in pediatrics,
ESHG argues that it is premature to look for later-onset conditions in children. Counseling should be offered and informed
consent is and should be a central ethical norm. Depending on developing evidence on penetrance, actionability, and
available resources, OGS pilots may be justified to generate data for a future, informed, comparative analysis of OGS and its
main alternatives, such as cascade testing.
Introduction
It is expected that in the near future many individuals with
an indication for genetic testing will have their exome or
now increasingly their entire genome sequenced (in this
document referred to as: ‘genome sequencing’), also
depending on the development of the total costs of diag-
nostic clinical sequencing. Of course, genome sequencing
allows targeted bioinformatics analysis of the raw sequen-
cing data (including uninterpreted data e.g., in Variant Call
Format (VCF) files) by using “virtual panels” or ‘phenotype
filters’ that are targeting genes most likely to be associated
with the symptoms of an individual. During such a targeted
analysis unsolicited, incidental findings may emerge, i.e.,
those which are unrelated to the primary clinical indication
for genome sequencing. Debate is ongoing about the pros
and cons of broadening the analysis by actively looking for
additional variants, unrelated to the initial purpose of test-
ing, which however could be relevant for the health pro-
spects and/or reproductive choices of the patient or the
patient’s family (so-called ‘secondary findings’; SFs). Such
discussions deal with medically ‘actionable’ information
associated with SFs which could help prevent a disease
from occurring, or facilitate the early management of a
disease once it develops (e.g., utilizing ‘precision medicine‘
approaches), diagnose a disease which is already present but
has not manifested clinically, thus far, or inform reproduc-
tive decisions.
Previous recommendations issued by the European
Society of Human Genetics (ESHG) on ‘Whole genome
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sequencing in health care’, did not explicitly explore the
analysis of SFs. The ESHG document stated that within the
health care context, genomic sequencing should focus on
the original test indication aimed at the identification of the
underlying genetic etiology of a disease and be ‘as targeted
as possible’; at least for the specific clinical and technical
context of genome sequencing at the time this consensus
statement was published [1]. This implied not actively
looking for SFs. The European stance has to be understood
in the context of genome sequencing in health care, where
many European countries have collectively funded health-
care systems. In this regard, screening programs undergo
evaluation of pros and cons before being implemented at a
regional or national level depending on the organization of
health care in the given European country. Screening pro-
grams tend to have limited funding from public resources,
and policy decisions to embark on one new activity typi-
cally demand the balancing of health care expenditure
elsewhere. In line with the ESHG recommendations, cau-
tionary policy statements were issued at that time also by
several national societies and authorities, such as the Ger-
man Society of Human Genetics [2], the Health Council of
the Netherlands [3], and the Canadian College of Medical
Geneticists [4]. Recently the French Agency of Biomedi-
cine document [5] is a further instance of this.
However, concurrently to the ESHG document, the
American College of Medical Genetics and Genomics
(ACMG) recommended a deliberate search for, and routine
analysis of, a predefined set of ‘actionable’ genomic var-
iants in each case of exome or genome sequencing irre-
spective of the medical indication for such testing [6].
ACMG uses the term ‘opportunistic screening’ for this
purpose, with the word ‘opportunistic’ referring to the
opportunity arising with the availability of the raw genome
sequencing-based data of individuals undergoing some
form of genome sequencing in the context of health care for
‘secondary analyses’. In the wake of the ACMG recom-
mendations, variations of this approach have also been
proposed or implemented in different European countries,
including the United Kingdom (100,000 Genomes Project,
ongoing) and France [7]. These initiatives have sparked
debate about the ethics of these strategies [8–10], also
leading to research projects aimed at charting the ethical,
legal, and social issues (ELSI) linked with opportunistic
screening in genomic medicine [11–15].
Opportunistic screening should be distinguished from the
use of selected multi-gene test panels in a clinical, diag-
nostic context. These are still currently utilized in order to
decrease analytical-, bioinformatic-, and data-storage related
costs and/or to increase specific target sequence coverage
and thus the analytical robustness of genetic testing. The
following example illustrates this distinction: If the indica-
tion for sequencing involves an oncological problem which
could be part of a specific rare hereditary cancer syndrome,
the applied test panel comprises multiple disease genes
associated with such syndromes, thereby reflecting clinical/
laboratory and genetic knowledge at a specific time point.
However, such broader scale genetic analysis still remains
within the frame of the diagnostic purpose of such testing.
By contrast, testing for ‘cancer predispositions’ not linked
with the suspected tumor syndrome(s) in question would
amount to ‘opportunistic screening’.
The ESHG regards it as its professional responsibility to
contribute to this ongoing debate. The present document
specifically discusses the pros and cons of opportunistic
genomic screening (OGS), understood as the deliberate
search for genetic variants unrelated to the diagnostic
question. The wider discussion of dealing with unsolicited
findings (UFs) in genomic medicine is beyond the scope of
the analysis presented here. This new ESHG position
statement contains relevant background information, ethical
reflection, and updated recommendations. A working group
of the ESHG’s Public and Professional Policy Committee
(PPPC) prepared the draft, which was then discussed by
PPPC and experts from the ESHG-EuroGentest Committee
and Quality subcommittee (https://www.eshg.org/index.
php?id=55). It was sent to ESHG members and selected
experts to solicit comments from 20 April until 20 May
2020. The authors have subsequently integrated the sug-
gestions where appropriate. The Board of ESHG has
approved the final version on 19 July 2020. In view of rapid
developments in the field and given the need for further
reflection, these Recommendations will need regular eva-
luation in the future.
Opportunistic screening in genomic
medicine
‘Opportunistic screening’ and ‘secondary findings’
The concept of opportunistic screening is not new. For
instance, in Family Medicine, general practitioners make
use of patient-initiated consultations to test routinely for
e.g., high blood pressure or analyze serum glucose/choles-
terol concentrations when screening for the metabolic syn-
drome. The concept of opportunistic screening has also
been used in radiology, e.g., when assessing the degree of
osteoporosis during computed tomography scans for other
indications [16]. When such tests are performed in patients
without a clinical indication for such testing, this amounts to
a form of screening. What makes it ‘opportunistic’, is that
those who might benefit from testing are only those who
happen to contact medical services for whatever reason.
Opportunistic screening differs from programmatic screen-
ing, where all members of a predefined target population are
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systematically invited for a uniformly organized and
externally evaluated screening service.
For the tested individuals, opportunistic screening does
not necessarily entail undergoing medical/laboratory pro-
cedures that they would otherwise not be subjected to. It
may imply carrying out an extra test (e.g., determining the
blood pressure) or extra venepuncture (e.g., examine serum
glucose/cholesterol concentrations). It may also consist of
an extended analysis of the data resulting from indicated
testing, as for instance when a doctor instructs the labora-
tory to check for a wider range of disease markers in a blood
test than those needed in view of a specific medical indi-
cation for which the test was ordered. Opportunistic
screening as discussed in this document, is of the latter kind:
it involves a wider analysis of the raw sequencing data that
are available when clinical genome sequencing is being
performed.
In genomic medicine, opportunistic screening consists of
a routine search for SFs, so called to mark the difference
from those answering (or partly answering) the clinical
question (‘primary findings’). Conceptually, SFs are also to
be distinguished from ‘incidental findings’ (IFs). Although
both terms (SF and IF) refer to results unrelated to the
original reason for testing, SFs are actively sought for,
whereas IFs are not. In the context of Next Generation
Sequencing (NGS), IFs are not necessarily rare, and the
ESHG has suggested that ‘UFs’ is a more appropriate
descriptive term than IFs [1]. In this document we use the
term ‘OGS’ to refer to the active or deliberate search for SFs
in the context of genome sequencing in health care.
Selected OGS-proposals and practices
This section summarizes three examples of OGS proposals
and practices, starting with the relevant recommendations of
the ACMG, as these may be considered as an initial frame
of reference. Two further examples of OGS are drawn from
France and the United Kingdom.
ACMG recommendations
The ACMG proposal recommends that laboratories per-
forming genome sequencing seek and report to the physi-
cian a minimum list of highly penetrant, actionable variants
in preselected candidate genes, regardless of the indication
for which the clinical sequencing was ordered and irre-
spective of the age of the patient [6]. Although the relevant
ACMG Working Group recommended reporting only var-
iants with a high likelihood of causing disease, it recognized
at the time “that there are limited data available in many
cases to make this assessment”, i.e., there was little infor-
mation on respective variant penetrance and/or expressivity.
While the “original” minimum list originally entailed 57
clinically relevant genes, this list was later decreased to 56
and then subsequently expanded to 59 [17]. The specific
genes under consideration pertain broadly to two major
medical domains, i.e., genes predisposing to specific forms
of cancer and those predisposing to cardiac diseases where
presymptomatic medical interventions may be of relevance.
The ACMG recommends refining and updating this list at
least annually, based on developing scientific and medical
evidence. Depending upon the specific genetic risk factor or
variant, carriers can make use of individualized preventive
options, including early or long-term medical imaging-
based monitoring, colonoscopy, prophylactic surgery, and
utilization of implantable cardioverter-defibrillators. After
some debate about the extent to which patients should be
given a choice, ACMG currently advocates an ‘opt out’
approach for patients who only want information relevant to
the original indication (i.e., ‘purpose’) for genome sequen-
cing [17]. Given the ACMG’s assessment of large benefits
and minimal risks, it would, as stated in a later clarification
document, be unethical not to offer OGS [18]. In a sup-
porting paper it is said that the ACMG Recommendations
may count “as evidence of the standard of care” in the case
of malpractice litigation [19].
The French Society of Predictive and Personalized Medicine
(SFMPP) recommendations
The SFMPP published its “Guidelines for reporting SFs of
genome sequencing in cancer genes” in August 2018 [7]. It
discusses multi-gene panels aimed at familial tumor syn-
dromes, including genes unrelated to the patient’s tumor.
The document speaks of SFs as “the results of a deliberate
(…) screening for alterations in genes that are not relevant
to the diagnostic indication for which the screening was
ordered.” As a consequence, the guidelines fit in with the
concept of OGS, as defined above. Using the criterion of
‘actionability’, an evaluation of the relevant risk and the
level of evidence, the SFMPP provisionally recommends
reporting information on 36 (so-called ‘class 1’) genes
related to specific forms of cancer in adults. While there is
significant overlap with the ‘cancer genes’ on the ACMG
list, the SFMPP lists many additional genes, for instance
PALB2, while excluding all the ‘cardiac genes’. With regard
to patient autonomy, the SFMPP insists on an explicit
informed consent procedure, rather than a mere opt-out
procedure. The document recommends a system of multi-
step (‘dynamic’) consent. The first step is in the context of
pretest counseling where patients are asked to indicate
whether they want to be informed about SFs in this subset
of genes or not. The second step is when patients are being
informed about the primary results. Here, they are given the
opportunity after further reflection (“with more autonomy”)
to confirm or refuse access to the information resulting from
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the search for SFs. This two-step counseling approach was
proposed by patient associations in order to limit the
potential psychological impact of OGS. The SFMPP
recommendations are limited to OGS in adults, pending
further debate and reflection on the acceptability of OGS for
cancer-related genes in minors.
We present here the SFMPP guidelines as an illustration
of a further OGS-proposal, while being aware that in
France, as elsewhere in Europe, the debate about the pros
and cons of OGS is still going on. Thus, the French Agency
of Biomedicine has recently adopted a draft of recommen-
dations for good practice with respect to the additional data
generated by NGS [5], which awaits ratification by the
French Ministry of Health, and state that “At the present
state of scientific knowledge, it is recommended not to
propose, in a diagnostic setting, a systematic analysis of
genes that are not related to the initial indication based on a
pre-established list”.
100,000 Genomes project and National Health Service
(NHS) England Genomic Medicine Service
The 100,000 Genomes Project (100 KGP) was initiated in
2013 with the aim of developing the implementation of
DNA sequencing technologies and thereby embedding
genomic medicine into routine health care. Recruitment into
100 KGP was primarily of patients with undiagnosed rare
disease or with specific cancers and this was completed in
2018. The NHS England Genomic Medicine Service is
being instigated, building on learning from the 100 KGP,
and introducing whole genome sequencing as a clinical test
in the NHS in England [20]. In October 2018, the UK
Secretary of State for Health and Social Care stated an
ambition to achieve the sequencing of 1 million genomes by
the NHS and the research project UK Biobank over 5 years,
including those with rare diseases and cancers, including a
population cohort [21].
Participants in 100 KGP gave consent for genome
sequencing with return of results related to their presenting
condition and the use of their data for research. Those
recruited were also offered the return of a limited set of
additional ‘looked for’ findings which would be confirmed
by accredited clinical diagnostic laboratories and then
usually returned to the patients by the specialist who had
recruited them to the 100 KGP. These SFs would be gen-
erated via a separate bioinformatics analysis on the genomes
of all those who had consented. There were two classes of
SFs: (i) medically actionable information (such as Lynch
syndrome) and (ii) information of reproductive significance
(in particular Cystic Fibrosis carrier status). Participants
could make the same or different decisions about the two
categories of SFs and they could also change their minds at
any time. Consent is sought for findings that were described
as actionable rather than specific, named conditions and
participants were informed that any conditions tested for
would be serious and that prevention or treatment was
available in the NHS. The offer to participants in relation to
reproductive findings (i.e., carrier status) was framed as
looking for variants that would not affect the individual but
could affect their future children [22].
In addition to questions of ‘actionability’, other factors
were considered in drawing up the list of SFs. Only those
disease genes were included which comprise high pene-
trance variants and where the association with disease and/
or the evidence for the efficacy of interventions was
strongly substantiated; where it would be technically pos-
sible to reliably detect variants in these genes using genome
sequencing, variants would only be reported where there
was a high confidence that they would be pathogenic or
likely pathogenic (capable of affecting function and causing
disease in a specific context). In addition, evidence of
clinical benefit from application of the genomic information
would be required, not simply the validity of the informa-
tion itself. This takes account of the potential burden on
NHS staff in validating and returning findings, and whether
care pathways for patients are established within the NHS.
However, the scenario of OGS crowding out resources for
indication-based pathways remains a matter of concern in
collectively funded health-care systems, such as in the UK.
In line with current recommendations on genetic testing
in children, the search for additional health-related findings
in minors is restricted to conditions where benefit could be
assumed during childhood and carrier testing is not offered.
At the time of writing (May 2020) the return of addi-
tional findings from 100 KGP has been delayed, but is
expected to go ahead in 2020. The return of SFs will be
accompanied by research on the feasibility and acceptance
of this procedure, together with a health economics
assessment. However, a decision regarding whether a
similar process of returning additional ‘looked for’ findings
will be offered in the NHS Genomic Medicine Service has
not yet been made.
Ethical exploration
In view of an ethical evaluation of OGS as exemplified in
the above proposals or practices, a preliminary question is
how they should be conceptualized for normative purposes.
There is more than one way of doing so, depending on
which elements are regarded as normatively relevant.
Firstly, the fact that OGS is carried out in the context of
individual patient medical care makes it a kind of in-
between concept: ‘screening’ in so far as the active search
for SFs goes beyond the original indication for testing, and
‘individual care’ in so far as this search is aimed at
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enhancing the medical benefits of a clinical test for the
patient. The ACMG strongly emphasizes the latter per-
spective [6]. It stresses that its recommendations ought to be
regarded as part of medical doctors’ fiduciary duty, i.e., as a
matter of providing good clinical care to the patient, who
would naturally expect the doctor to actively look for
(actionable) information relevant to his or her health. To the
extent that this does amount to screening, this is seen as
different from the kind of screening to which the normative
framework applies that was developed by the WHO
(‘Wilson and Jungner’) [23] and other national and inter-
national authorities [24]. The difference being precisely that
this framework was meant for organized screening pro-
grams targeting population groups in a public health context
[25], rather than for the clinical context for which OGS is
being proposed [26]. However, this may be too swift a
dismissal of the wider relevance of this framework also for
OGS. From a normative perspective, the distinguishing
characteristic of medical screening is not so much the
context in which it is performed (whether public health or
health care), but the lack of an indication for having this
specific test or investigation in those to whom screening is
offered [27]. As famously stated by Cochrane and Holland
[28], the non-indicated nature of screening entails a more
precarious benefits-to-risks balance in comparison to
indication-based testing: “If a patient asks a medical prac-
titioner for help, the doctor does the best he can. He is not
responsible for defects in medical knowledge. If, however,
the practitioner initiates screening procedures he is in a very
different situation. He should in our view, have conclusive
evidence that screening can alter the natural history of
disease in a significant proportion of those screened”. In
view of this difference, the core requirements of the tradi-
tional screening framework include (1) evidence that for
those being screened, this balance is clearly favorable
(proportionality) and (2) explicit informed consent by those
to whom the screening offer is made (autonomy). More-
over, especially when screening is offered in the context of
collectively funded health care it requires (3) a justification
in terms of considerations of distributive justice.
Secondly, given that what we are dealing with here is the
wider analysis of raw sequencing data that have become
available as a result of testing, a further possible under-
standing is that providing this information is a matter of the
individuals’ right to information that others have obtained
about them. However, this seems to ignore the difference
between raw sequencing data and whatever meaningful
genomic information can be extracted from those data,
either with clinical or personal utility. Even if the patient
has a right to his or her raw data (including e.g., VCF files),
it does not follow that medical professionals should perform
the analysis needed to turn that data into information. If they
decide to do so, this requires a separate justification, which
leads back to the above discussion of OGS as a form of
screening in the context of clinical care.
We intend to contribute to further debate about the
conditions for responsible OGS by considering how such an
offer relates to the three core requirements of the screening
framework: proportionality, autonomy, and justice, while
differentiating between OGS as offered to adults and as
offered to children (or minors) [12].
OGS offer to competent adult patients
Proportionality
Since OGS is offered to those who do not have a medical
problem or medical history-based reason for having the
relevant sequencing data analyzed, and because generating
medical information may also have adverse effects, it is not
obvious that a specific OGS proposal is on balance bene-
ficial for those to whom the offer to search for SFs is made.
Whether it is, can only be determined based on scientific
evidence—not just considering the potential benefits that it
may yield, but also specifying the possible harms that it
may bring. Given that OGS is a form of genetic screening,
any benefits and harms may affect not just the individual
whose genome data are analyzed, but their genetic relatives
as well. Notwithstanding the requirement that the pro-
portionality balance must be positive for the persons being
screened in the first place, these ‘third party’ effects should
be considered as well.
Possible benefits The possible benefits of OGS are pri-
marily medical. First and foremost, OGS is aimed at
yielding information allowing the primary or secondary
prevention of serious genetic diseases where early or
presymptomatic medical interventions could prevent their
development or at least substantially delay their onset,
notably forms of hereditary cancer syndromes and cardi-
ogenetic disorders, not only in the screened individual
with a ‘positive’ result, but also their genetic relatives. A
recent study provided evidence that 2.6% of healthy
individuals would be shown to carry an increased risk for
a severe dominant disease if routinely screened for var-
iants in the ACMG minimum list of genes [29]. The health
benefits following from this may be considerable,
depending, however, on several factors. The positive
predictive value of the SFs targeted in the OGS panel
must be high, the effectiveness of the preventative inter-
ventions or measures recommended to those found to be
at risk should be scientifically proven, and access to those
interventions as well as to relevant counseling must be
guaranteed. Whether the latter conditions will be appro-
priately met, is contextually dependent on the health-care
system.
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A second type of medical benefit regards a more
favorable risk-benefit ratio of medical interventions or
treatments that the patient might have to undergo some-
where in the future. These include screening for genetic
variants causing serious adverse reactions to anesthetics
(already included in the ACMG list) or for pharmacoge-
nomic (PGx) variants. As argued in one of the updated
versions of the ACMG recommendations, the latter may be
especially relevant where concerning “variants related to
commonly prescribed medications as well as medications
associated with serious adverse events for which there is
greater urgency surrounding actionability” [17].
In addition to direct or future health benefits, OGS may,
thirdly, provide reproductive benefits, in so far as any
positive findings allow the persons being screened or their
relatives to make informed reproductive choices (e.g.,
aimed at avoiding the conception or birth of a child with
a serious genetic disorder). The current inclusion of cystic
fibrosis-carrier status in the OGS approach taken in the UK
represents a limited step in this direction.
A further increase of possible benefits is conceivable if
more variants will be found to meet the criteria of
pathogenicity and actionability and the list would be
expanded. Apart from single genetic variants, future
incorporation of genome-wide polygenic risk scores (PRS)
might be considered if these would be shown to have
clinical utility in order to reduce the risk of developing
common disorders like diabetes type 2 and coronary heart
disease [30]. Likewise, the reproductive benefits of OGS
may be enlarged by including carrier status for a potentially
large number of serious recessive disorders.
Risks The potential harms and disadvantages of OGS are
of different but interrelated categories: psychological,
social, and medical. Some of these are of a more general
nature, linked with OGS per se, while others depend on the
context, content, and conditions of specific OGS-practices.
Both psychological and medical harms may arise when
OGS is introduced based on insufficient evidence regarding
the health impact (e.g., pathogenicity, penetrance, and
expressivity) of variants in the listed disease genes. Looking
for such variants in unaffected individuals has been
criticized for lack of validation for general population
screening; the penetrance might be lower and uncertain in
the absence of family history [8, 31]. Also, ACMG
underlines the importance of ongoing research into
penetrance and expression (range of severity) [26]. Clearly,
the penetrance of some of the variants in genes on the
ACMG list has been overestimated [32–34]. Given that
OGS is offered to individuals that do not have a higher a
priori risk than the general population with regard to the SFs
on the list, penetrance figures based on data from affected
families may overestimate their risk of actually developing
the disorder [35]. For instance, in 2004 the penetrance of
pathogenic variants in the SDHB gene (succinate dehy-
drogenase B, causing pheochromocytoma and paragan-
glioma) was estimated to be 77% by 50 years of age [36],
however, two recent papers concluded that in healthy
relatives (“non-probands”) it is closer to 20% by 50 years of
age [37, 38]. Overestimation of the health risks related to
OGS findings may lead to unnecessary anxiety. It may also
lead to the persons being screened being unnecessarily
exposed to iatrogenic harms of invasive procedures under-
taken as diagnostic or preventive measures [39], or to
psychological distress of long-term surveillance. Variants
have been misclassified as pathogenic on the basis of the
understanding at the time of testing for both tumor
syndromes and cardiogenetic conditions, especially in
ethnically diverse populations [40]. This is not to deny that
the penetrance of genetic variants in the general population
(although it might be lower than their penetrance in affected
families) may still be sufficiently high to warrant their
inclusion in OGS. If so, the lower magnitude of risk may
well require preventive strategies that reflect a different
proportionality balance as compared to prevention in
affected families.
In order to avoid that people being screened are
confronted with the psychological burden of being told
they are at risk of developing a serious disorder for which
no options for treatment or prevention exist, OGS proposals
rightly insist on the condition that to qualify for OGS, SFs
should also be ‘actionable’. However, psychosocial harm
may still ensue when actionability is too easily assumed [9],
or when only limited actionability is taken as a sufficient
reason for inclusion in the list of targeted SFs. A good
example of this is the only ‘partial’ actionability of
(germline) TP53 pathogenic variants predisposing for Li-
Fraumeni syndrome [41].
Assuming that OGS is only offered for SFs where there is
sufficient evidence of a significant health impact (in terms
of pathogenicity and penetrance) and a clear actionability
(in terms of options for treatment and prevention promising
to considerably ameliorate the health prospects for those
with positive findings), OGS still comes with psychosocial
concerns and challenges, given that little is known about
how people unfamiliar with the relevant disorders will deal
with positive findings and related options for prevention and
reproductive choice [9]. Counseling should be provided by
a professional with relevant expertise regarding the
additional findings. However, we need to consider how
OGS can be offered in a way that empowers people rather
than undermines their confidence in their health. What are
their counseling needs in connection to OGS-findings and
with regard to the possible sharing of genetic information
with relevant family members? Given the different setting,
premature extrapolations from (mostly reassuring)
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psychological research in carriers in affected families
should be avoided. Though some recent studies of the
psychological impact of receiving ‘positive’ SFs were to
some extent reassuring [42–44], more research is needed.
These questions are even more important if OGS would be
offered at a time when patients are trying to cope, deal with
and give meaning to the totally different genetic problem for
which they are having indicated clinical sequencing for
example, sequencing after sudden cardiac death in a child.
The societal risks of OGS, in addition to the potential
transformation of everyone who receives an SF after genetic
testing into a “patient-in-waiting” [45], primarily regard
possible adverse consequences for access of people ‘at high
genetic risk’ to particular insurance schemes [46], or to
specific jobs. Given the recent report that variants related to
sudden cardiac death were found in 1% of asymptomatic
individuals [47], the professions that would be at risk in this
regard include bus drivers, aircraft pilots, etc. Several
studies suggest that there is minimal evidence for such
societal repercussions, especially when the disorders for
which people prove to be at high risk are preventable or at
least treatable [48]. In view of the highly different
jurisdictions regarding the legal protection of applicants
for jobs and insurances, these societal risks are probably to a
considerable extent contextual.
As the proportionality prerequisite for offering screening
is inherently linked with what has been termed the
‘evidentiary model’ [49], the ESHG observes that at least
for the moment, there are simply too many questions,
unknowns, uncertainties, and concerns to conclude that
current OGS-proposals clearly meet this criterion—let alone
that they would define the standard of care. This holds a
fortiori for the suggestion to extend the concept into
incorporating PRS in clinical care [30], also given the
current apparent bias towards European-derived populations
[50]. This is reinforced by the dependence of any putative
benefits from PRS on the patient’s behavioral response to
risk information, which in many studies has not been
encouraging [51].
Respect for autonomy
After an initial debate about the extent to which a patient
should be given a choice with regard to adding OGS to
indicated testing [18, 52], the ACMG recommends an ‘opt
out’ approach. Patients who want to have the clinically
indicated sequencing without having their raw sequencing
data searched for SFs, can refrain from OGS if they so wish.
As this presents the search for SFs as the default position
that doctors would recommend, it is at odds with the nor-
mative framework for screening, according to which the
non-indicated nature of any screening offer requires those
offering it to seek the full and explicit consent of those to
whom the offer is made [24]. The problem with an ‘opt out’
for OGS is that patients may be insufficiently aware of the
fact that the search for SFs is unrelated to the medical
indication for genome sequencing, and that whether or not
to have OGS is therefore something that needs separate
consideration. Moreover, even when patients understand
that OGS is indeed a form of screening, the message con-
nected with offering it as a standard procedure that only
some might want to opt-out from, may stand in the way of
helping the patient to make a truly autonomous decision.
The SFMPP recommendations insist that “the patient’s
autonomy and desire to know or to ignore SF results must
be respected” and stress that the patient “could decline at
any time to be informed about the SF’s even if they pre-
viously gave their approval” [7]. Pujol et al. [7] differentiate
between a first step at which written consent for SF is given,
a second step in which this consent is renewed (or not) and
primary findings are discussed, and a third step in which the
actual SFs are discussed. Such an approach may well help
avoid a professional conflict of duties; it is a different matter
not to screen for certain genes out of respect for the patient’s
right not to know, and not to report available findings of
great relevance for the patient’s own health or that of his or
her close relatives [53]. Ideally, one should try to avoid
burdening professionals by generating health information
that the patient does not want to receive. Although this
cannot be completely avoided in the genomic era, an ade-
quate informed consent procedure for OGS should try to
minimize this problem as far as possible (like in other
contexts of genetic testing). For example, the raw data
might only be analyzed after the second step of the SFMPP
approach. This would allow tested individuals to become
better informed and allow them additional time for reflec-
tion and might thereby reduce the chance that the patient
later claims the right not to know about SF’s after an initial
consent given for the generation of such findings, possibly
generating the conflict of duties mentioned.
If genome sequencing were offered as a package of
enrolment combining health care and research in a hybrid
offer, where sequencing was only available if consent to
research was given, then there could be concerns about so-
called ‘undue inducement’, as Dheensa et al. [54] have
discussed for the 100 kGP. The aims of sequencing could be
blurred: both research and health care are at stake. The
hybrid offer might lead people needing sequencing in a
health care setting to decide to participate in sequencing
because of potential advantages outside of the initial med-
ical indication, such as receiving SFs, while also influencing
them to participate in research. The hybrid nature of such
initiatives raises questions concerning the consent process
by distracting potential participants from its core elements
and potentially violating the principle of respect for
autonomy [54].
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A final issue is whether patients should be given the
option to decide for themselves whether to be screened for
only part of the list of SFs targeted in a specific OGS offer.
A categorical rejection of allowing any form of ‘persona-
lization’ of OGS seems at odds with the principle of respect
for patient autonomy. Acknowledging this principle would
seem to require professionals to as much as possible respect
patients’ wishes with regard to controlling what information
to receive as a result of being tested. For instance, patients
may want to limit the search for SFs to pharmacogenomics
variants or to carrier status for recessive disorders. What
patients would regard as meaningful choices in this regard
and whether providing those choices would be feasible in
practice is a matter for evaluation in the context of future
OGS-pilots.
Justice
As OGS is screening in the context of health care, as it
involves the further analysis of raw data that becomes
available during the indicated testing, the marginal costs of
screening are relatively low in comparison to establishing
an entire screening program. Nonetheless, bioinformatics
analysis and confirmation of detected variants (when man-
ual variant curation and their clinical assessment will still be
necessary in the foreseeable future) will remain costly
despite rapid progress in machine learning-based proce-
dures for variant prioritization. Moreover, genetic counsel-
ing costs may still be considerable given the potential need
to recontact [55] and repeatedly counsel tested individuals
as new evidence gradually accrues which informs the
interpretation of variants [56, 57]. These aspects need to be
taken into account when OGS is offered in a way that would
acknowledge the principle of respect for autonomy. Costs of
OGS will further increase if subsequent cascade testing
among relatives of people with ‘positive’ OGS results
occurs. The fact that OGS will lead to downstream costs for
the health system is not problematic. However, this is a
further reason for only offering OGS for variants with a
proven health impact, so the costs of unnecessary inter-
ventions are avoided and the concept of ‘overdiagnosis’ as
documented is dealt with e.g., in the field of radiology [58].
Moreover, in solidarity-based health-care systems, the sce-
nario of OGS crowding out resources for indication-based
care pathways raises concerns about just prioritization [59].
In view of the potential ‘add-on’ costs of OGS it is
important to consider if alternative approaches could be
more cost-effective. Most notably, cascade testing targeting
the relatives of a proband in case of clearly pathogenic,
highly penetrant, and actionable variants, such as in
BRCA1- and BRCA2-related hereditary breast and ovarian
cancer, Lynch syndrome and Familial Hypercholester-
olaemia has been recommended. The United States Centers
for Disease Control and Prevention Office of Genomics and
Precision Public Health has defined such ‘Tier 1’ genomic
applications as ‘having significant potential for positive
impact on public health based on available evidence-based
guidelines and recommendations’ [60–63]. Such cascade
testing is, however, currently underutilized [64]. Whether
cascade testing, OGS or a combination of both should be
given priority from a distributive justice perspective is an
important question that may allow for a different answer in
countries that have already implemented cascade testing for
a larger number of the relevant conditions in their health
system, as compared to those that have not. Where OGS is
used for genetic risk factors that allow for prevention
through lifestyle modification rather than medical inter-
ventions, collective measures, such as general health edu-
cation or measures of health protection targeting the
environment or the workplace may be considered as alter-
natives [65]. The case for prioritizing such measures, if
proven effective, is strong, especially in under-resourced
countries. However, in more affluent countries, distributive
justice may allow for combining collective prevention and
well-defined OGS. It also needs to be noted that there
remains a strong bias towards European-derived variant
frequencies currently present in broadly used variant data-
bases with data from under-resourced countries still gen-
erally missing, which may exacerbate health disparities.
Individuals may potentially be harmed if there is insufficient
knowledge to characterize variants as pathogenic or not in
ethnically diverse populations [66].
OGS also raises a question about formal justice. OGS is
only offered to individuals who happen to have an indica-
tion for genome sequencing. However, with regard to the
SFs targeted in OGS these patients do not have a higher a
priori risk than other members of the general population,
who are not offered screening for the same conditions. This
could be considered as a morally problematic inequality of
access to a health service that ideally should be avoided.
Along the same line it has been argued that screening for
likely pathogenic and actionable variants should be offered
to a general population [10]. However, as stressed by the
ACMG in an earlier statement, offering the same benefits to
all would come with the much higher costs of setting up the
infrastructure for programmatic screening, which would be
far less cost-effective than OGS [6]. Given the opportunity
costs of population screening for the same set of variants,
the only way of securing equality of access may well
amount to denying access to all. Such ‘leveling-down’
justice (‘if not all can profit, then no one should’) is clearly
not in anyone’s interest. Moreover, it could be argued that
the formal justice problem of OGS is mitigated by the fact
that chances of becoming a patient with an indication for
clinical sequencing are equally distributed in the population.
However, people who achieved higher education and
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income are often over-represented when applying for
genetic counseling [67]. Indeed, it could be seen as
exacerbating pre-existing inequities in access to health care,
as described by Tudor Hart’s ‘Inverse care Law’ [68].
Further justice considerations arise with the different
health care settings in which OGS could be offered. For
instance, if ‘actionability’ consists of costly treatment that
many people could not afford [69], screening for the rele-
vant variants will be more beneficial for some than for
others.
OGS in minors
Traditional guidelines state that predictive genetic testing of
minors should be limited to conditions where options for
treatment or prevention are available that must be initiated
during childhood/adolescence [70–72]. All further pre-
dictive testing should be postponed until minors are mature
enough to decide for themselves about undergoing genetic
testing. Arguments for this position are either based on
moral rights or on morally relevant consequences. Relevant
arguments of the former refer to the minor’s right to
informational self-determination (as part of ‘the child’s right
to an open future’). Consequence-based arguments point to
how the burdens of risk status information may harm the
child for example by overshadowing its psychosocial
development.
To the extent that these recommendations should also
apply to OGS, this significantly limits the list of variants
that minors’ sequencing data could be screened for, at least
where young children are concerned that have not reached
sufficient maturity to decide about OGS for themselves.
Although OGS for certain conditions that are actionable
early in life (such as MEN type 2A, hereditary arrhythmias
such as long QT and Brugada syndrome) and for pharma-
cogenomic variants including variants modifying the indi-
vidual reaction to anesthetics could still be possible, this
would rule out OGS for most of the ACMG list.
However, proponents of OGS in minors as recommended
by the ACMG argue that the context for which those tra-
ditional guidelines for predictive genetic testing of children
were drafted, namely presymptomatic testing in relatives of
an index case, is substantially different from that of OGS
[19]. In the former context, postponement of testing minors
for late-onset disorders is without consequences both for
them and for their relatives, as no information about their at
risk status will thereby be “lost”. Refraining from OGS in
minors with an indication for genome sequencing, by con-
trast, amounts to missing what may well be a one-off
opportunity of generating potentially life-saving informa-
tion both for the minors themselves and their relatives.
Whether this reasoning justifies OGS for later-onset
conditions in minors is a matter for further debate. Is there
evidence that minors may be harmed by telling their parents
that they (i.e., those minors) are at risk of a serious but
actionable later-onset disorder? If not, are the possible
future benefits for the child sufficiently weighty to trump
the remaining concerns about violating the minor’s right to
informational privacy? How convincing in this regard is the
notion of OGS as a one-off, unique, opportunity that should
not be missed, given that minors will grow up in an era
where genome sequencing may become a routine part of
health care? Alternatively, does the argument ultimately rest
on the interests that the minor’s relatives may have in not
letting this opportunity for generating important health
information be wasted? Then indeed the question becomes
one of justifying the screening of children in order to benefit
others. Are the interests of family members sufficiently
weighty to override the concerns related to the minor’s right
to informational privacy? However, a less antagonistic way
of framing this debate is that where the health or repro-
ductive interests of the parents are concerned, serving those
interests is also in the interest of the child who depends on
the ability of its parents to provide for its daily care.
The suggestion is that, in the near future, genome
sequencing may become a standard procedure in prenatal
diagnostics and neonatal screening for serious and action-
able congenital diseases which lends further urgency to this
debate [73–75].
Recommendations of ESHG: opportunistic
screening in genomic medicine
According to earlier ESHG Recommendations on NGS in
health care [1], genomic analysis should be as targeted as
possible, at least for the time being. Taking account of
further developments in science and clinical practice, this
new document confirms the 2013 viewpoint that a broader
analysis than that needed to answer the diagnostic question
raises complex issues in clinical practice. This is not to say
that all forms of OGS are a priori unsound. However, if
OGS is being offered, it should take the form of pilots
combined with rigorous evaluation studies aimed at redu-
cing present uncertainties that could stand in the way of
determining its proportionality as a health care service.
(1) Performing a broader analysis than needed to answer
the diagnostic question amounts to a form of screening, for
which the general framework of screening criteria is
applicable. In addressing the question whether such OGS
would meet the relevant and widely endorsed criteria for
(genetic) screening, ethical principles of proportionality,
respect for autonomy, and justice should be considered.
(2) In light of the non-indicated nature of OGS, there is a
strong burden of proof that such screening is on balance
beneficial for those to whom it is offered. Although so far
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no evidence of psychosocial harm has emerged, more
research is needed. In the light of this, it is too early to
recommend OGS as part of the professional standard.
(3) In view of the many uncertainties, directly impacting
the required proportionality of any OGS, the ESHG con-
tinues to recommend a generally cautious approach. Any
OGS should be embedded in adequate pilot and evaluation
studies in order to enable optimal decision making about the
proportionality of OGS. Priority should be given to well-
known, highly penetrant variants, predisposing for genetic
disorders which can be adequately and effectively prevented
and/or treated. The selection may well be contextual, taking
account of both the penetrance of particular variants in a
given population, which may differ between populations in
Europe, and the capacity of the different health-care systems
to integrate relevant, complex, counseling, and (preventive)
treatment services for proven bearers of these variants.
Apart from genetic and medical uncertainties, and imple-
mentation issues, the psychological impact of OGS merits
attention. Crucial questions include how to enable patient
empowerment and address counseling needs.
(4) Clear procedures and criteria are needed for decision
making about the composition and extension of the list of
genetic variants included in any OGS, and its imple-
mentation. A wider debate, involving all relevant stake-
holders, especially patients, is of utmost importance.
Patients should not be reduced to the object of well-
intended medical deliberations and interventions.
(5) Informed consent should be a central ethical norm in
the framework regarding genetic screening generally and
OGS particularly. Alternatives such as opting out and,
particularly, a coercive offer of OGS are problematic. A
multi-step (‘dynamic’) consent approach may be helpful but
needs further empirical study. The patient’s right not to
know should be respected as far as reasonably possible,
while allowing professionals to still inform the patient about
specific findings of great importance for the patient’s own
health or that of his or her close relatives.
(6) When counseling for OGS, the provisional nature of
current knowledge on penetrance should be addressed as
well as potential crossovers with research and options for
recontacting in case new scientific evidence of clinical
relevance arises.
(7) Depending on developing evidence on penetrance
and actionability, but also taking account of the resources
available for health care in European countries, OGS pilots
may be justified to generate data for a future, informed,
comparative analysis of OGS and its main alternatives,
namely (the offer of) universal genomic screening for
highly penetrant, actionable variants, and (more systematic)
cascade testing in relatives of probands affected with
(avoidable) diseases caused by highly penetrant genetic
variants.
(8) OGS in minors for variants leading to later-onset
actionable conditions needs further ethical scrutiny. There
seem to be no valid principled objections to OGS in
children for PGx variants and variants leading to early-
onset actionable conditions. Likewise OGS for late-onset
disorders could be offered for minors who, because of,
for example, profound intellectual disability, are not
expected to become competent later (if such targeted
OGS would meet the principles of proportionality and
justice).
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